<DOC>
	<DOCNO>NCT00995059</DOCNO>
	<brief_summary>Rationale : Giving bortezomib low dos chemotherapy total-body irradiation donor stem cell transplant peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving sirolimus tacrolimus transplant may stop happen . Purpose : This phase I/II trial study side effect best dose bortezomib donor stem cell transplant treat patient multiple myeloma .</brief_summary>
	<brief_title>Bortezomib Before Donor Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>Objectives : I . To determine maximum tolerate dose ( MTD ) bortezomib use novel condition regimen patient undergo allogeneic stem cell transplantation multiple myeloma . II . To evaluate tolerability feasibility novel condition regimen GVHD prophylaxis strategy incorporate several anti-myeloma agent , include bortezomib , patient undergo allogeneic stem cell transplantation multiple myeloma . III . To obtain initial assessment efficacy novel condition regimen . Outline : This phase I dose-escalation study bortezomib follow phase II study . Reduced-Intensity Conditioning : Patients receive bortezomib IV undergo fractionate total-body irradiation day -5 -2 . Patients receive thymoglobulin IV 6 hour day -5 -2 melphalan IV 30 minute day -4 -3 . Allogenic Stem Cell Transplantation : Patients undergo bone marrow peripheral blood stem cell transplant day 0 . Graft versus Host Disease Prophylaxis : Beginning day -3 , patient receive oral sirolimus taper begin day 61 . Beginning day -2 , patient receive oral IV tacrolimus taper begin day 101 . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>ECOG performance status ( PS ) 0 , 1 , 2 Diagnosis symptomatic multiple myeloma High risk myeloma define progressive disease = &lt; 12 month high dose chemotherapy autologous HSC transplant presence poor prognostic feature deletion chromosome 13 hypodiploidy standard cytogenetics , ( 4 ; 14 ) fluorescence situ hybridization ( FISH ) , ( 14 ; 16 ) FISH , 17p FISH , plasma cell label index &gt; = 3 % Availability HLA fullymatched 1 mismatch relate donor lowresolution HLA type locus A , B , C , DRB1 DQB1 HLA fullymatched unrelated donor highresolution type locus A , B , C DRB1 least lowresolution locus DQB1 Recovery toxicity previous chemotherapy ( excludes grade 1 neurotoxicity hematological toxicity ) Physically psychologically capable undergo bone marrow PBSC transplant Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Female subject either postmenopausal surgically sterilize willing use acceptable method birth control study Male subject agrees use acceptable method contraception duration study Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV hear failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities NOTE : Prior study entry , ECG abnormality screen document investigator medically relevant Significant cardiac dysfunction define left ventricle ejection fraction &lt; 40 % presence symptomatic coronary artery disease Significant pulmonary disease define FEV &lt; 50 % CLCO &lt; 50 % predict value Pre exist peripheral neuropathy grade &gt; 1 Significant renal dysfunction define estimate creatinine clearance &lt; 50 ml/min Significant liver dysfunction define total bilirubin &gt; = 2 x upper limit normal ( ULN ) AST , ALT &gt; = 3 x ULN Seroreactive HIV , HTLV I II , HBV , HCV Presence uncontrolled bacterial , viral , fungal infection Known allergy component investigational treatment regimen require ancillary treatment Considered unable tolerate include dos total body irradiation due previous treatment radiation Female subject pregnant breastfeeding Other active concurrent malignancy Prior allogeneic bone marrow/peripheral blood stem cell transplant Received investigational drug = &lt; 14 day prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>